Ausgabe 2/2023
Inhalt (20 Artikel)
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations
Atsushi Osoegawa, Yohei Takumi, Takafumi Hashimoto, Shotaro Nakatsuji, Mayu Hori, Mayu Sakai, Takashi Karashima, Miyuki Abe, Michiyo Miyawaki, Kenji Sugio
In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma
Sara Varatanovic, Tobias Maier, Sega Al-Gboore, Stefan Stoiber, Sam Augustine Kandathil, Clemens Quint, Charlotte Brennus, Gregor Heiduschka, Lorenz Kadletz-Wanke, Faris F. Brkic
Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway
Mehmet Ali Karaselek, Serkan Kuccukturk, Tugce Duran, Ahmed Nuri Kursunlu, Mustafa Ozmen, Ceren Bozdag, Selman Alkan, Alper Varman, Mehmet Aykut Yildirim, Tevfik Kucukkartallar, Celalettin Vatansev
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
Hana Dostálová, Radek Jorda, Eva Řezníčková, Vladimír Kryštof
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
Siqi Shang, Yunshuo Chen, Xuejiao Yang, Ying Yang, Wenbo Wang, Yueying Wang
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer
Rana Vafaei, Zohreh Khaki, Malihe Salehi, Neda Jalili, Mohammad Reza Esmailinejad, Ahad Muhammadnajad, Seyed Mahdi Nassiri, Alireza Vajhi, Shima Moradi Kalbolandi, Roya Mirzaei, Leila Farahmand
Mesenchymal stem cells: a trojan horse to treat glioblastoma
Antoine Chartouni, Antoine Mouawad, Marc Boutros, Fouad Attieh, Nicolas Medawar, Hampig Raphaël Kourie
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
Tong Zhou, Huan Yi, Chan Zhu, Yangyang Yu, Qianru He, Mingzhe Xiao, Chuang Qi, Tianyu Lu
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Yingying Yang, Qingmei Zheng, Xinmei Wang, Shuyong Zhao, Wenshu Huang, Linchao Jia, Cuicui Ma, Shicong Liu, Yongpeng Zhang, Qianqian Xin, Yan Sun, Shansong Zheng
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study
Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F. Hottinger, Thomas Kaindl, Marc Engelhardt, Michalina Marszewska, Heidi Lane, Patrick Roth, Anastasios Stathis
Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects
Linlin Hu, Ting Dou, Qiuyue Sun, Lu Tang, Mingmin Cai, Wei Qian, Huiping Wang
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
Antonio Jimeno, Joaquina Baranda, Wade T. Iams, Jong Chul Park, Monica Mita, Michael S. Gordon, Matthew Taylor, Neesha Dhani, Alexis D. Leal, Prakash Neupane, Cathy Eng, Oladapo Yeku, Alain Mita, Justin C. Moser, Marcus Butler, Scott M. Loughhead, Julia Jennings, Nathan R. Miselis, Rui-Ru Ji, Nitya Nair, Martin Kornacker, Ricardo F. Zwirtes, Howard Bernstein, Armon Sharei
A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors
Zhuang Kang, Shenglan Li, Yi Lin, Yongsheng Li, Ying Mao, Jing Zhang, Ting Lei, Haidan Wang, Yangzhi Su, Yang Yang, Jingbo Qiu, Wenbin Li
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
James Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, Her-Shyong Shiah, Kang-Yun Lee, Te-Chun Hsia, Makiko Uno, Nigel Crawford, Hiroshi Terakawa, Wen-Chi Chen, Gensuke Takayama, Ching Hsu, Ying Hong, Carline Saintilien, Joseph McGill, Gee-Chen Chang
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Danny N. Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A. Soff
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer
Ilya Tsimafeyeu, Galina Statsenko, Liubov Vladimirova, Natalia Besova, Elena Artamonova, Grigory Raskin, Ivan Rykov, Anastasia Mochalova, Igor Utyashev, Svetlana Gorbacheva, Vasily Kazey, Evgenia Gavrilova, Nadezhda Dragun, Vladimir Moiseyenko, Sergei Tjulandin
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis
Chunjiang Wang, Hanqing Zeng, Weijin Fang, Liying Song
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Hiroyuki Marusawa, Shinichiro Nakamura, Toshifumi Tada, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Chikara Ogawa, Takashi Sato, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
Christopher N. Nguyen, Swaminathan P. Iyer, Madeleine Duvic, Prajak J. Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O. Huen
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
Shota Omori, Koji Muramatsu, Takuya Kawata, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Takashi Sugino, Toshiaki Takahashi